Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153050 | 1.00 | LY96 (0.44) | LY96HSD11B1POLBMEN1KMT2A | |
| SCHEMBL2152900 | 0.84 | HSD11B1 (0.46) | LY96HSD11B1POLBMEN1KMT2A | |
| SCHEMBL2152897 | 0.84 | HSD11B1 (0.46) | LY96HSD11B1POLBMEN1KMT2A | |
| SCHEMBL2153381 | 0.82 | MAOB (0.43) | POLBMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL2153378 | 0.82 | MAOB (0.43) | POLBMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL13906648 | 0.82 | CYP1A2 (0.46) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL27533555 | 0.82 | KDM4E (0.54) | LY96POLBMEN1KMT2AMAPT | |
| SCHEMBL15369550 | 0.81 | LMNA (0.47) | POLBKMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL29138776 | 0.79 | MTNR1A (0.51) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL5122754 | 0.79 | CA12 (0.42) | POLBMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833789-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS BV (NL) | 2011-07-06 | — | — | EP | disclosed |
| US-7732621-B2 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP ASSETS B.V. (NL) | 2010-06-08 | — | — | US | disclosed |
| CN-100482671-C | Chiral monophosphorous ligand, synthetic method and its use | SHANGHAI INST ORGANIC CHEM (CN) | 2009-04-29 | — | — | CN | disclosed |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| EP-1833789-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSMIP Assets B.V. (NL) | 2007-09-19 | — | — | EP | disclosed |
| CN-1304403-C | Monophosphine ligand having C2 symmetric skeleton, synthesis method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676838-A1 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP Assets B.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
| CN-1651443-A | Monophosphine ligand having C2 symmetric skeleton, synthesis method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2005-08-10 | — | — | CN | disclosed |
| CN-1616470-A | Chiral monophosphorous ligand, synthetic method and its use | SHANGHAI INST ORGANIC CHEM (CN) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | IDO2, IDO1, KYNU | LY96 4011/4885HSD11B1 772/4885POLB 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.